Celgene ( CELG) estimates, price target were boosted at Cantor Fitzgerald. Shares are now seen reaching $156. Estimates were also upped, as the company raised its guidance, Cantor said. Buy rating.

CME Group ( CME) numbers were raised at Citigroup. Estimates were increased on better interest rate volatility and capital market activity, said Citigroup. Price target goes to $82.

Dana Holdings ( DAN) estimates were reduced at UBS. Estimates were reduced to reflect fewer share buybacks, said UBS. Price target is $24.

Embraer ( ERJ) estimates were reduced at UBS. Estimates were reduced to reflect weaker margin performance and higher R&D expenses, said UBS. Price target is $40.

Gilead Sciences ( GILD) numbers were raised at UBS. Estimates were raised to now include preliminary idelalisib estimates, said UBS. Price target is $72.

General Motors ( GM) numbers were increased at Citigroup. Estimates were raised on the second-quarter beat, confidence in pickup truck pricing and lower interest expense, said Citigroup. Price target goes to $45.

Hershey ( HSY) estimates, price target were increased at BMO Capital. Estimates were raised through 2014. Higher sales are driving margin expansion, BMO Capital said. Market Perform rating and new $95 price target.

McGraw Hill ( MHFI) numbers were raised at UBS. Estimates were raised to reflect the second-quarter beat and higher margins in 2014, said UBS. Price target is now $66.

Maxim Integrated numbers were cut at Citigroup. Estimates were cut on low-quality industrial performance and Samsung retrograde risk, said Citigroup. Price target goes to $27.

Precision Castparts numbers were cut at Citigroup. Estimates were cut to reflect near-term weakness in commercial OE engine demand, said Citi. Price target goes to $266.

Teradyne ( TER) numbers were lowered at UBS. Future earnings estimates were lowered based on lower growth expectations in the wireless test business, UBS said. Price target was reduced to $20.

T-Mobile ( TMUS) numbers were raised at UBS. Estimates were raised as JUMP is now expected to provide an incremental boost to EBITDA, said UBS. Price target is now $28.

WellPoint ( WLP) numbers were raised at UBS. Estimates were raised on a strong quarter and reduced costs, said UBS. The new price target is $87.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

Cramer: Dominoes Are in Play Today

Advance Auto Parts Is About to Hit an Inflection Point, Barclays Says

Gap Joins Retailers With Decent Quarters; Posts Surprise Earnings Beat